Hasil Pencarian  ::  Simpan CSV :: Kembali

"Human Epidermal Growth Factor (hEGF) merupakan polipeptida yang terdiri atas 53 asam amino. Protein hEGF berfungsi untuk proliferasi sel epitel dan epidermis secara in vitro dan in vivo. Protein hEGF dikode oleh gen EGF. Gen EGFsyn telah dikonstruksi secara sintetik untuk optimasi kodon pada Escherichia coli. Optimasi kodon berfungsi untuk meningkatkan ekspresi protein rekombinan pada E. coli. Subkloning gen EGFsyn ke plasmid pJ404 yang mengandung gen peptida sinyal endoxylanase sangat diperlukan dalam ekspresi protein hEGF rekombinan pada E. coli. Kendala ekspresi protein rekombinan pada E. coli yaitu terbentuknya badan inklusi di sitoplasma. Peptida sinyal endoxylanase digunakan untuk mentranslokasi protein ke periplasma. Digesti gen EGFsyn dan vektor pJ404 dengan enzim NheI dan BamHI diperlukan untuk persiapan subkloning dan ekspresi protein hEGF ke periplasma. Hasil penelitian menunjukkan bahwa gen EGFsyn dan plasmid pJ404 berhasil dipotong dan siap digunakan untuk subkloning.

---

Human Epidermal Growth Factor (hEGF) is a polypeptide consisted of 53 amino acids. Its function is to promote epithel and epidermis cells proliferation in vitro and in vivo. It is encoded by EGF gene. An EGFsyn has been constructed to optimize codon usage in Escherichia coli. Codon optimization enhances recombinant protein expression in E. coli. Subcloning EGFsyn gene to a plasmid carrying endoxylanase signal peptide gene is important for recombinant hEGF expression in E. coli. One of the problem expressing recombinant protein in E. coli is the accumulation of inclusion bodies in cytoplasm. Endoxylanase signal peptide is used to translocate protein to periplasm. Digestion of EGFsyn gene and plasmid pJ404 by enzyme NheI and BamHI is needed for preparation of subcloning and hEGF expression to periplasm. The results showed that EGFsyn gene and plasmid pJ404 was digested and can be used for subcloning."

"Infeksi human papillomavirus tipe 16 (HPV16) dapat menyebabkan kanker servikk, penyebab kematian no 2 di dunia. Salah satu pencegahannya adalah dengan imunisasi. Vaksin komersil saat ini merupakan vaksin viral like particles (VLP) diproduksi pada sistem ekspresi yeast dan baculovirus. Sebagai upaya penyediaan vaksin dengan harga lebih ekonomis telah dilakukan pengembangan vaksin DNA dan protein rekombinan L1 HPV16 yang diekspresikan di prokariota. Antigenitas vaksin DNA dan L1 rekombinan diujikan dalam peneltian ini. Penelitian dimulai dari pemindahan L1 dari pUC L1 HPV16 ke pCDNA3.1, ekspresi L1 rekombinan dalam prokariota, pengamatan pembentukan VLP oleh L1 rekombinan dengan transmission electron microscope (TEM), pengujian antigenitas kombinasi vaksin DNA dan protein rekombinan pada BALB/c. Hasil menunjukkan pcDNA3.1 L1 berhasil diperoleh yang dibuktikan dengan analisis enzim restriksi dan sekuensing. L1 rekombinan berhasil membentuk VLP, vaksin komposisi 12,5 μg pcDNA3.1 L1 dikombinasikan 2 μg L1 rekombinan menginduksi titer antibodi endpoint tertinggi pada pengambilan serum terakhir yaitu 23.55 (p<0.05) dibandingkan vaksin 12,5 μg pcDNA3.1 L1 (2.775) dan 2 μg L1 rekombinan (10.45) yang diberikan secara terpisah setelah 3 kali imunisasi. Sebagai kesimpulan pCDNA3.1L1 berhasil diperoleh, protein L1 rekombinan dapat membentuk VLP dan pemberian kombinasi pcDNA3.1 L1 dan L1 rekombinan menginduksi respon kekebalan tubuh lebih bagus dibandingkan pemberian secara terpisah.

---

Infection with human papillomavirus type 16 (HPV16) can cause cervical cancer, the second cause of death in the world. One way to prevent it is with a barrier. The current commercial vaccine is a viral like particle (VLP) vaccine produced on yeast and baculovirus expression systems. As an effort to provide a vaccine at a more economical price, a DNA vaccine and a recombinant L1 HPV16 protein that are expressed in prokaryotes have been developed. The antigenicity of recombinant DNA and L1 vaccines was tested in this study. The research started with the transfer of L1 from pUC L1 HPV16 to pCDNA3.1, expression of recombinant L1 in prokaryotes, assessment of VLP formation by recombinant L1 with transmission electron microscopy (TEM), testing the antigenicity of a combination of DNA vaccines and recombinant protein on BALB/c. The results showed that pcDNA3.1 L1 was successfully obtained, as evidenced by restriction enzyme analysis and sequencing. The recombinant L1 succeeded in forming a VLP, the composition of the vaccine 12.5 µg PCDNA3.1 L1 combined 2 µg L1 recombinant induced the highest endpoint antibody titer (10.45) which was given 23.55 (p <0.05) compared to the 12.5 µg vaccine PCDNA 3.1 L1 (2,775) and 2 µg L1 recombinant (10.45) given by 3 times. As a conclusion, pCDNA3.1L1 was successfully obtained, recombinant L1 protein can form VLP and provide a combination of recombinant pcDNA3.1 L1 and L1 induce an immune response better than administration separately."